Palonosetron manufacturers
- Palonosetron USP/EP/BP
-
- $1.10 / 1g
-
2021-07-10
- CAS:149653-99-6
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | Palonosetron Basic information |
| Product Name: | Palonosetron | | Synonyms: | [r-(r*,r*)]-2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benz[de]isoquinolin-1-one;CID 148211;1H-Benz[de]isoquinolin-1-one, 2-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-, (3aR)-;Palonosetron USP/EP/BP;(R)-2-((R)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benzo[de] isoquinolin-1-one | | CAS: | 149653-99-6 | | MF: | C19H24N2O | | MW: | 296.41 | | EINECS: | | | Product Categories: | | | Mol File: | 149653-99-6.mol |  |
| | Palonosetron Chemical Properties |
| Boiling point | 470.4±45.0 °C(Predicted) | | density | 1.24 | | pka | 9.77±0.33(Predicted) |
| | Palonosetron Usage And Synthesis |
| Indications | Palonosetron is approved by the US FDA for acute and delayed CINV and PONV. | | Biological Activity | Palonosetron is a highly selective, high-affinity 5-HT3 receptor antagonist. Due to its structural difference from the first-generation 5-HT3 receptor antagonists, palonosetron has an affinity for the 5-HT3 receptor at least 30 times that of other similar drugs. | | in vitro | Palonosetron is neither an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4/5 (CYP2C19 not studied) nor does it induce the activity of CYP1A2, CYP2D6 or CYP3A4/5. |
| | Palonosetron Preparation Products And Raw materials |
|